Abstract

The current study investigated the therapeutic potential of Ph-triazole in silico and in vitro against pancreatic cancer. Common targets between Ph-triazole and pancreatic cancer, notably P53 protein, were identified using the venny 2.1.0 tool and imported into the String database to construct the protein-protein network. Box plot revealed that the most prominent hub gene TP53 is strongly up-regulated in pancreatic tumor tissues (N = 179) compared to normal tissue samples (N = 171), and stage plots confirmed that its upregulation is found during all four stages of the disease. Survival analysis of the pancreatic cancer patients revealed a strong correlation between TP53 gene overexpression and low overall survival and disease-free survival. Molecular docking showed that Ph-triazole exhibits a strong binding affinity for P53 protein. In vitro data also confirmed the anti-proliferative effect of Ph-triazole in pancreatic cancer cell models. Therefore, Ph-triazole can act as an anti-proliferative agent for pancreatic cancer and needs to be investigated further by in vivo studies.

Affiliated Institutions

Related Publications

Publication Info

Year
2025
Type
article
Volume
20
Issue
12
Pages
e0334618-e0334618
Citations
0
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

0
OpenAlex

Cite This

Ningbo Zhang, Xingxing Li, Fangyuan Li et al. (2025). Ph-triazole as a therapeutic agent for pancreatic cancer: Synthesis, in silico, and in vitro evaluation. PLoS ONE , 20 (12) , e0334618-e0334618. https://doi.org/10.1371/journal.pone.0334618

Identifiers

DOI
10.1371/journal.pone.0334618